Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada
The goal is to deliver greater value to customers, doctors, and the broader healthcare ecosystem
This predictive technology empowers people with diabetes to take preventive action before complications arise
Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing
The inspection concluded with zero form 483 observations
The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo
The lab will facilitate the development of herbal and natural-based solutions
Bayer Co.Lab AdVenture platform will accelerate biotech innovation through global investment networks
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
